innoscripta SE Tops German Growth Charts with Clusterix Platform Driving Revenue Surge
innoscripta SE leads Germany's publicly listed companies with unparalleled growth driven by its Clusterix platform, showcasing impressive financial prospects despite cautious investor sentiment.
- • innoscripta SE achieved the highest CAGR among German listed companies from 2021 to 2024.
- • Clusterix platform is central to the company's rapid growth, aiding R&D documentation and tax grants for 2,500+ companies.
- • Expected EBIT is at least €80 million with projected revenues of €140 million, indicating strong profitability.
- • Investor caution exists despite growth, partly due to concerns over AI competition, but management remains confident with stock buybacks.
Key details
German technology company innoscripta SE has emerged as the fastest growing publicly listed company in Germany, according to the Financial Times/Statista "Europe’s Fastest Growing Companies 2026" ranking. The company recorded the highest average annual growth rate (CAGR) from 2021 to 2024, more than doubling the growth rate of the next highest German company.
This outstanding growth is primarily fueled by innoscripta's cloud-based platform, Clusterix, which supports over 2,500 research and development-intensive companies by structuring data collection, documentation, and management of R&D activities. Clusterix particularly aids companies in efficiently leveraging tax research grants, which has helped innoscripta establish a scalable and focused business model.
Listed on the Scale segment of the Frankfurt Stock Exchange since May 2025 under the ticker 1INN, innoscripta anticipates an EBIT of at least €80 million on projected revenues of €140 million, marking one of the highest profitability margins within the German tech sector. Despite the robust financial outlook and recent stock buybacks worth approximately €5.5 million at €70 per share reflecting management confidence, some investors remain cautious due to emerging competition from AI technologies.
innoscripta’s unique commission-based revenue model, charging clients only upon successful acquisition of research allowances, reduces upfront costs for customers and highlights the company's innovative approach in the market. This strong performance and strategic positioning underscore innoscripta’s leading role in Germany’s tech-driven financial growth landscape.
This article was translated and synthesized from German sources, providing English-speaking readers with local perspectives.
Source articles (2)
Source comparison
Current share price
Sources report different current share prices for innoscripta SE.
stock3.com
"innoscripta SE has a current share price of €75.20."
boerse.de
"Recent stock buybacks worth approximately 5.5 million EUR at a price of 70 EUR have also been reported."
Why this matters: One source states the share price is €75.20, while the other mentions a price of €70. This discrepancy is significant as it affects investor perception and valuation of the company.
Latest news
Major Survey Reveals German Public’s Strong Interest and Barriers in Healthy Aging and Longevity
Germany Faces Climate Policy Challenges Amidst Record-Breaking 2026 Heatwave
German Football Transfer Market Nears Deadline with Major Moves and Ongoing Challenges
Underdog Spirit and Squad Challenges Shape DFB-Pokal First Round Matches
AfD Strengthens Lead Across All Social Groups Ahead of Sachsen-Anhalt 2026 Election
German Companies Show Only Modest Climate Protection Investment Growth Through 2027
The top news stories in Germany
Delivered straight to your inbox each morning.